NumerixS Investment Technologies Inc lowered its position in Boston Scientific Co. (NYSE:BSX) by 24.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,440 shares of the medical equipment provider’s stock after selling 1,760 shares during the period. NumerixS Investment Technologies Inc’s holdings in Boston Scientific were worth $206,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc raised its stake in shares of Boston Scientific by 1.4% in the third quarter. Vanguard Group Inc now owns 101,453,358 shares of the medical equipment provider’s stock worth $3,905,954,000 after purchasing an additional 1,367,053 shares during the last quarter. Advisors Asset Management Inc. purchased a new stake in shares of Boston Scientific in the fourth quarter worth approximately $1,267,000. Financial Gravity Companies Inc. purchased a new stake in shares of Boston Scientific in the fourth quarter worth approximately $46,000. Capital Investment Advisory Services LLC purchased a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $64,000. Finally, CIBC Private Wealth Group LLC increased its position in shares of Boston Scientific by 21.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 7,532 shares of the medical equipment provider’s stock valued at $266,000 after acquiring an additional 1,320 shares during the last quarter. Institutional investors and hedge funds own 90.80% of the company’s stock.
In other Boston Scientific news, SVP Maulik Nanavaty sold 3,038 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $40.11, for a total transaction of $121,854.18. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Xin Warren Wang sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $38.45, for a total value of $384,500.00. The disclosure for this sale can be found here. Insiders have sold 103,157 shares of company stock worth $4,041,963 in the last 90 days. Company insiders own 0.66% of the company’s stock.
Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.35 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.36 by ($0.01). Boston Scientific had a net margin of 18.08% and a return on equity of 24.65%. The firm had revenue of $2.49 billion for the quarter, compared to analysts’ expectations of $2.54 billion. During the same quarter in the previous year, the business earned $0.33 EPS. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. On average, equities analysts expect that Boston Scientific Co. will post 1.55 earnings per share for the current fiscal year.
BSX has been the subject of a number of research analyst reports. BTIG Research reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Thursday, April 25th. Argus increased their price target on Boston Scientific from $43.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, February 13th. Canaccord Genuity decreased their price target on Boston Scientific from $45.00 to $43.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Evercore ISI raised Boston Scientific from an “in-line” rating to an “outperform” rating and set a $36.20 price target for the company in a research report on Monday, May 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price target on shares of Boston Scientific in a research report on Monday, May 13th. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. Boston Scientific has an average rating of “Buy” and an average price target of $41.87.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Recommended Story: Trade War
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.